CYP2D6 gene amplification and the risk of acute myeloblast leukemia

Pharmacological Reports

Volumn 59, Issue SUPPL. 1, 2007, Pages 167-172

  Łapiński, Łukasz ^a   Agúndez, Jose A G ^b   Wiela Hojeńska, Anna ^a   Ganczarski, Grzegorz ^a   Orzechowska Juzwenko, Krystyna ^a   Wołowiec, Dariusz ^a   Głowacka, Krystyna ^a   Kuliczkowski, Kazimierz ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

Acute myeloblastic leukemia; Amplification; CYP2D6; Polymorphism; Ultra rapid metabolizers

Indexed keywords

CYTOCHROME P450 2D6;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER RISK; CHI SQUARE TEST; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HUMAN; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL SIGNIFICANCE;

EID: 38049134978     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Agungez JAG: Cytochrome P450 gene polymorphism and cancer. Curr Drug Metabol, 2004, 5, 211-224.
2. Agundez JAG, Gallardo L, Ledesma MC, Lozano L, Rodriguez-Lescure A, Pontes JC, Iglesias-Moreno MC et al.: Functionally active duplications of the CYP2D6 gene are more prevalent among larynx and lung cancer patients. Oncology, 2001, 61, 59-63.
3. Agundez JAG, Ledesma MC. Benitez J, Ladero JM, Rodrigez-Lescure A, Diaz-Rubio E, Diaz-Rubio M: CYP2D6 genes and risk of liver cancer. Lancet, 1995, 345, 830-831.
4. Anwar WA, Abdel-Rahman SZ, El-Zein RA, Mostafa HM, Au WW: Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients. Carcinogenesis, 1996, 17, 1923-1929.
5. Blanco JG, Edick MJ, Hancock ML, Winick NJ, Dervieux T, Amylon MD, Bash RO et al.: Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics, 2002, 12, 605-611.
6. Bowen DT Frew ME, Rollinson S, Roddam PL, Dring A, Smith MT, Langabeer SE, Morgan GJ: CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplication. Blood, 2003, 101, 2770-27774.
7. Bradford LD: CYP2D6 allele frequency in European Caucasian, Asians, Africans and their descendants. Pharmacogenomics, 2002, 3, 229-243.
8. Brockmoller J, Cascorbi I, Kerb R, Roots I: Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res, 1996, 56, 3915-3925.
9. Daly AK, Brockmoller J, Broly F, Eichelbaum M, Evans WE, Gonzales FJ, Huang JD et al.: Nomenclature for human CYP2D6 alleles. Pharmacogenetics, 1996, 6, 193-201.
10. Gallou C, Longuemaux S, Delomenie C, Mejean A, Martin N, Martinet S, Palais G et al.: Association of GSTT1 non-null and NAT1 slow/rapid genotypes with von Hippel-Lindau tumour suppressor gene transversions in sporadic renal cell carcinoma. Pharmacogenctics, 2001, 11, 521-535.
11. Hasler JA, Estabrook R, Murray M, Pikuleva I, Waterman M, Capdevila J, Holla V et al.: Human cytochromes P450. Mol Aspects Med, 1999, 20, 1-137.
12. Infante-Rivard C, Labuda D, Krajinovic M, Sinnett D: Risk of childhood leukemia associated with exposure to pesticides and with gene polymorphisms. Epidemiology, 1999, 10, 481-487.
13. Kaisary A: Genetic predisposition to bladder cancer, ability to hydroxylate debrisoquine and mephenytoine as risk factors. Cancer Res, 1987, 45, 5488-5492.
14. Kelsey KT, Wrensch M, Zuo ZF, Miike R, Wiencke JK: A population-based case-control study of the CYP2D6 and GSTT1 polymorphisms and malignant brain tumors. Pharmacogenetics, 1997, 7, 463-468.
15. Krajinovic M, Labuda D, Mathonnet G, Labuda M, Maghrabi A. Champagne J, Sinnett D: Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin Cancer Res, 2002, 8, 802-810.
16. Krajinovic M, Labuda D, Richer C, Karimi S, Sinnett D: Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1. CYP2D6. GSTM1, and GSTT1 genetic polymorphisms. Blood, 1999, 93, 1496-1501.
17. Krajinovic M, Richer C, Sinnett H, Labuda D, Sinnett D: Genetic polymorphisms of N-acetyltransferases 1 and 2 and gene-gene interaction in the susceptibility to childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev, 2000, 9, 557-562.
18. Lapinski L, Wiela-Hojenska A, Ganczarska G, Orzechowska-Juzwenko K, Wolowiec D, Glowacka K, Hurkacz M et al.: Clinical significance of oxidation and acetylation genetic polymorphism in patogenesis of acute mycloblastic leukemia (Polish). Probl Ter Monit, 2006, 17, 11-19.
19. Lemos MC, Cabrita FJ, Silva HA, Vivan M, Placido F, Regateiro FJ: Genctic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogenesis, 1999, 20, 1225-1229.
20. Lovlie R, Daly AK, Molven A, Idle JR, Steen VM: Ultratapid metabolizers of debrisoquine: characterization and PCR- based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 1996, 392, 30-34.
21. Marsh JCW, Chowdry J, Parry-Jones N, Ellis SW, Muir KR, Gordon-Smith EC: Study of the association between cytochrome P450 2D6 and 2E1 genotypes and risk of drug and chemical-induced idiosyncratic aplastic anaemia. Br J Haem, 1999, 104, 266-270.
22. Matthias C, Bockmuhl U, Jahnke V, Jones PW, Hayes JD, Alldersea J, Gilford J et al.: Polymorphism in cytochrome P450 CYP2D6. CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers. Pharmacogenetics. 1998, 8, 91-100.
23. Niewinski P, Orzechowska-Juzwenko K, Hurkacz M, Rzemislawska Z, Jazwinska-Tarnawska E, Milejski P, Forkasiewicz Z: CYP2D6 extensive, intermediate, and poor phenotypes and genotypes in a Polish population. Eur J Pharmacol, 2002, 58, 533-535.
24. Niewinski P, Orzechowska-Juzwenko K, Milejski P: Pharmacogenetics. In: Clinical Pharmacology. Significance in Clinical Practice (Polish). Ed. Orzechowska-Juzwenko K. Górnicki Wydawnictwo Medyczne, Wrocław, 2006, 145-161.
25. Niewinski P, Orzechowska-Junvenko K, Pawlik J, Milejski P, Dembowski J, Swiebodzki L, Lorenz J: Genetically determined oxidation and acetylation polymorphism in patients with urinary bladder cancer (Polish). Probl Ter Monitor, 1994, 4, 43-45.
26. Orzechowska-Juzwenko K, Niewinski P, Pawlik J, Milejski P, Dembowski J, Swiebocki L, Lorenz J: Genetically determined sparteine oxidation and sulfadimidine acetylation polymorphism in patients with non-occupational urinary bladder cancer. Mat Med Pol, 1994, 26, 145-148.
27. Roddam PL, Rollinson S, Kane E, Roman E, Moorman A, Cartwright R, Morgan GI: Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia. Pharmacogenetics, 2000, 10, 605-615.
28. Sachse C, Brockmoller J, Barter S, Roots I: Cytochrome P4502D6 variants in Caucasian population: allele frequencies and phenotyping consequences. Am J Hum Genet 1997, 60, 284-295.
29. Sachse C, Smith G, Wilkie MJ, Barrett JH, Waxman R, Sullivan F, Forman D, Bishop DT, Wolf CR, Colorectal Cancer Study Group: A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis, 2002, 23, 1839-1849.
30. Sinnett D, Krajinovic M, Labuda D: Genetic susceptibility to childhood acute lymphoblastic leukemia. Leuk Lymphoma, 2000, 38, 447-462.
31. Smith C, Gough A, Leigh P, Summers B, Harding A: Debrisoquine bydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet, 1992, 339, 1375-1377.
32. Steijns LSW, van der Weide J: Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication. Clin Chem, 1998, 44, 914-917.
33. Strange RC, Ellison T, Ichii-Jones F, Bath J, Hoban P, Lear JT, Smith AG et al.: Cytocbrorne P450 CYP2D6 genotypes: association with hair colour, Breslow thickness and melanocytc stimulating hormone receptor alleles in patients with malignant melanoma. Pharmacogenetics, 1999, 9, 269-276.
34. Wadelius M, Autrup JL, Stubbins MJ, Andersson SO, Johansson JE, Wadelius C., Wolf CR et al.: Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer. Pharmacogenetics, 1999. 9, 313-340.
35. Wolf CR, Smith G: Pharmacogenetics Br Med Bull, 1999, 55, 366-386.
36. Worrall SF, Corrigan M, High A, Starr D, Matthias C, Wolf CR, Jones PW et al.: Susceptibility and outcome in oral cancer: preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6. Pharmacogenetics, 1998, 8, 433-439.
37. Xie HG, Kim RB, Wood AJJ, Stein CM: Molecular basis of ethnic differences in drug disposition and response. Ann Rev Pharmacol Toxicol, 2001, 41, 815-850.
38. Zanger UM, Fischer J, Raimundo S, Stuven T, Evert BO, Schwab M, Eichelbaum M: Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics, 2001, 11, 573-585.